Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Pharma-Bio Serv (PBSV) over the last 17 years, with Q4 2025 value amounting to -$9202.0.

  • Pharma-Bio Serv's Cash from Financing Activities changed N/A to -$9202.0 in Q4 2025 from the same period last year, while for Oct 2025 it was -$1.8 million, marking a year-over-year decrease of 103.04%. This contributed to the annual value of -$1.8 million for FY2025, which is 103.04% down from last year.
  • Per Pharma-Bio Serv's latest filing, its Cash from Financing Activities stood at -$9202.0 for Q4 2025.
  • Pharma-Bio Serv's 5-year Cash from Financing Activities high stood at $41113.0 for Q4 2021, and its period low was -$1.8 million during Q2 2021.
  • Its 5-year average for Cash from Financing Activities is -$657808.8, with a median of -$8197.5 in 2024.
  • In the last 5 years, Pharma-Bio Serv's Cash from Financing Activities surged by 40034.08% in 2021 and then plummeted by 6224829.88% in 2022.
  • Over the past 5 years, Pharma-Bio Serv's Cash from Financing Activities (Quarter) stood at $41113.0 in 2021, then crashed by 105.79% to -$2379.0 in 2022, then surged by 66.71% to -$792.0 in 2023, then plummeted by 120.58% to -$1747.0 in 2024, then crashed by 426.73% to -$9202.0 in 2025.
  • Its Cash from Financing Activities stands at -$9202.0 for Q4 2025, versus -$5004.0 for Q3 2025 and -$1.7 million for Q2 2025.